With modest global decline in the number of tuberculosis (TB) deaths and TB incidences over the past decade, TB still continues to spread and raise havoc in several regions of the world. In recent years, this situation is further worsened by the HIV pandemic and emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Especially, MDR and XDR-TB are associated with high morbidity and mortality due to inability of the current treatment options to cure TB effectively. In addition, there is need for alternative methods to prevent disease transmission. MDR and XDR-TB are therefore a major public health concern worldwide. Several alternative mechanisms such as pharmacokinetic variability, induction of efflux pumps and suboptimal drug penetration into TB lesions are now considered to play a crucial role in acquired resistance to anti-tuberculous drugs rather than poor compliance alone.
This special issue will examine several aspects of development of MDR-TB and its treatment including new insights into the biology of transmission, newer diagnostic tools, design of new interventions, drug delivery and dosing mechanisms. This special issue will further highlight optimal treatment management, role of newer and repurposed drugs, pharmacokinetic and pharmacodynamic considerations along with preventive strategies for MDR-TB.
Insights into development and treatment of multidrug-resistant tuberculosis (MDR-TB)
Nisha Nanaware-Kharade Pharmacokineticist in Department of Clinical Pharmacology Pharmaceutical Product Development (PPD) LP USA Submission date: 2017-12-01